Wilms’ tumor 1 enhances Cisplatin‐resistance of advanced NSCLC.

Wilms’ tumor 1 (WT1) is an oncogene that has been correlated with tumor progression, bad prognosis and chemo‐resistance in Non‐Small‐Cell lung cancer (NSCLC). Here, we found that WT1 expression is significantly higher in NSCLCs than in benign controls, and that Cisplatin‐resistant patients display a notable increase in WT1 expression following relapse. In vitro, WT1 levels were associated with the IC50 of NSCLC cells and increased along with treatment time and dose of Cisplatin. Furthermore, WT1 enhanced Major Vault Protein (MVP) transcription via binding to its promoter. Therefore, WT1 may be a potential therapeutic target for solving resistance.WT1 increased when relapse occurred in NSCLC. WT1 increased with time and dose of Cisplatin exposure. WT1 enhanced MVP transcription via binding to its promoter. [ABSTRACT FROM AUTHOR]